Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias

By sjmartinez • May 7, 2025

Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, Tanzawa F, Numata M, Bixby DL, Erba HP, Podoltsev N, Schiller GJ, Kumar P, Lesegretain A, Isoyama T, Seki T, Daver N, Andreeff M. Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias. Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-2764. Epub ahead of print. PMID: 40327322.

Tags: Hematology/Oncology, Publications

Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

Kudo M, Yamashita T, Finn RS, Galle PR, Ducreux M, Cheng AL, Tsuchiya K, Sakamoto N, Hige S, Take R, Yamada K, Nakagawa Y, Takahashi[...]

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database

Bachet JB, de Gramont A, Raeisi M, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JR, Mayer RJ, Lichtman SM, Benson[...]

Diagnostic Challenges in a Case of Hemophagocytic Lymphohistiocytosis Likely Induced by Coxiella burnetii

Tai JW, Wu P. Diagnostic Challenges in a Case of Hemophagocytic Lymphohistiocytosis Likely Induced by Coxiella burnetii. Cureus. 2025 Apr 2;17(4):e81634. doi: 10.7759/cureus.81634. PMID: 40322410;[...]